Evidence map›Paper›PMID 35891608›Full record

ArticleCancer medicine2023

Autologous stem cell transplantation (ASCT) for acute myeloid leukemia in patients in first complete remission after one versus two induction courses: A study from the ALWP of the EBMT.

Arnon Nagler, Jacques-Emmanuel Galimard, Myriam Labopin, Didier Blaise, William Arcese, Silvia Maria Trisolini, Depei Wu, Arnaud Pigneux, Gwendolyn Van Gorkom, Marie-Thérèse Rubio and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Arnon NaglerDivision of Hematology, Sheba Medical Center, Tel Hashomer, Israel.ORCID 0000-0002-0763-1265
Jacques-Emmanuel GalimardEBMT Statistical Unit, Paris, France.
Myriam LabopinEBMT Statistical Unit, Paris, France.
Didier BlaiseProgramme de Transplantation & Therapie Cellulaire; Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France.
William ArceseRome Transplant Network, Università Tor Vergata, Rome, Italy.
Silvia Maria TrisoliniHematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.
Depei WuFirst Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, China.
Arnaud PigneuxService d'Hématologie et Thérapie Cellulaire, CHU Bordeaux, Bordeaux, France.
Gwendolyn Van GorkomUniversity Hospital Maastricht, Department of Internal Medicine Hematology/Oncology, Maastricht, The Netherlands.
Marie-Thérèse RubioDepartment of Hematology, Brabois Hospital, Centre Hospitalier Régional Universitaire (CHRU), Nancy, France.
Tobias Gedde-DahlDepartment of Hematology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital-Rikshospitalet, Oslo, Norway.
Anne HuynhHematology Department, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France.
Francesco LanzaRomagna Transplant Network, Ravenna, Italy.
Norbert-Claude GorinDepartment of Clinical Hematology and Cellular Therapy, Saint-Antoine Hospital, AP-HP, Sorbonne University, Paris, France.ORCID 0000-0002-0108-5769
Mohamad MohtyDepartment of Clinical Hematology and Cellular Therapy, Saint-Antoine Hospital, AP-HP, Sorbonne University, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAchieving complete remission (CR) is the main goal in AML treatment and a prerequisite for successful autologous stem cell transplantation (ACT).

methodsComparing results of peripheral blood ACT in patients with AML in CR1 attained following 1 versus 2 chemotherapy courses transplanted in 2000-2019.

resultsPatients 1532 (84%) with one and 293 (16%) patients with two induction chemotherapies courses (a total of 1825 patients) were included in the study. Follow-up was 7.9 (95% CI: 7.4-8.4) and 7.7 (95% CI: 7.0-8.6) years (p = 0.8). Time from diagnosis to ACT was 4.7 (range, 3.9-5.8) versus 5.7 (range, 4.7-7.1) months (p < 0.001), respectively. Leukemia free survival (LFS) and overall survival (OS) at 5 years were inferior for patients achieving CR1 with 2 versus 1 course of chemotherapy: 26.6% versus 41.7% (HR = 1.42 [95% CI: 1.22-1.66], p < 0.001) and 36.2% versus 53.3%, (HR = 1.48 [95% CI: 1.25-1.75], p < 0.001), and 5-year relapse incidence (RI) was higher: 67.2% versus 52.3%, (HR = 1.46 [95% CI: 1.25-1.72], p < 0.001). Five-year non-relapse mortality (NRM) was 6.2% versus 6.0% for patients with 2 versus 1 chemotherapy courses, and did not differ significantly (HR = 1.31 [95% CI: 0.81-2.10], p = 0.27).

conclusionsLFS and OS were inferior and relapse rate was higher in AML patients who received two inductions chemotherapy courses to reach CR1 before being autografted. AML patients who required 2 induction courses to achieve remission, may be offered allogeneic transplantation rather than an autologous one in an attempt to reduce their high RI and improve outcomes.

Indexed as

Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteHumansRecurrenceRemission InductionRetrospective StudiesTransplantation, AutologousTransplantation ConditioningTransplantation, Homologousacute myeloid leukemiaautologouscomplete remissioninduction chemotherapystem cell transplantation

Identifiers

PMID35891608
PMCPMC9883552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.